PRESS RELEASE

Q3 2020 — Press release

Q3 2020PDF · 18 pages428 KB
JOHNSON & JOHNSON REPORTS 2020 THIRD-QUARTER RESULTS:
• 	Sales of $21.1 billion reflecting an overall and operational increase of 1.7%*, and adjusted
operational increase of 2.0%* despite the estimated negative impact of the COVID-19 pandemic
• 	EPS of $1.33 increased 101.5%; adjusted EPS of $2.20 increased 3.8%*
• 	Company increasing guidance for Full Year Reported Sales by $1.0 billion and Adjusted EPS by
$0.15 driven by the strength of the recovery and strong underlying business fundamentals
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter
2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by
better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in
Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and
Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we
boldly fight the COVID-19 pandemic. Our world-class R&D team is working tirelessly to advance the Phase 3 trials of
our COVID-19 vaccine and to uphold the highest standards of transparency, safety and efficacy; while other dedicated
teams provide ongoing support to hospitals and patients as they return to sites of care, and ensure patients and
consumers have the medicines and products they need. This resilient mindset, combined with our strategic capabilities
and execution excellence, increase our optimism for continued recovery in 2020 and strong momentum entering into
2021.”
OVERALL FINANCIAL RESULTS:
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
4 Excludes intangible amortization expense and special items
($ in Millions, except EPS) 	2020 	2019 	% Change
Reported Sales 	21,082	$ 	20,729	$ 	1.7%
Net Earnings 	3,554 	1,753 	102.7%
EPS (diluted) 	1.33	$ 	0.66	$ 	101.5%
Non-GAAP*
($ in Millions, except EPS) 	2020 	2019 	% Change
Operational Sales 1,2 	1.7%
Adjusted Operational Sales 1,3 	2.0%
Adjusted Net Earnings 1,4 	5,868 	5,672 	3.5%
Adjusted EPS (diluted) 1,4 	2.20	$ 	2.12	$ 	3.8%
THIRD QUARTER
THIRD QUARTER

-- 1 of 18 --

2
REGIONAL SALES RESULTS:
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
SEGMENT SALES RESULTS:
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
Adjusted
($ in Millions) 1
Adjusted
2020 2
Adjusted
2019 2
Adjusted
Reported 2
Adjusted
Operational 1,2
Adjusted
Currency2
Adjusted
Operational 1,3
U.S. 	11,086	$ 	10,791	$ 	2.7% 	2.7% 	- 	2.8
International 	9,996 	9,938 	0.6% 	0.6% 	0.0 	1.1
Worldwide 	21,082	$ 	20,729	$ 	1.7% 	1.7% 	0.0 	2.0
THIRD QUARTER 	% Change
Adjusted
($ in Millions) 1
Adjusted
2020 1
Adjusted
2019 1
Adjusted
Reported2
Adjusted
Operational 1,2
Adjusted
Currency1
Adjusted
Operational 1,3
Consumer Health 	3,514	$ 	3,469	$ 	1.3% 	3.0 	(1.7) 	3.1
Pharmaceutical 	11,418 	10,877 	5.0% 	4.6 	0.4 	4.7
Medical Devices 	6,150 	6,383 	(3.6)% 	(3.9) 	0.3 	(3.3)
Worldwide 	21,082	$ 	20,729	$ 	1.7% 	1.7 	0.0 	2.0
% Change	THIRD QUARTER

-- 2 of 18 --

3
SEGMENT COMMENTARY:
Consumer Health
Consumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, increased by
3.1%*, inclusive of the net negative impact of COVID-19 primarily in international over-the-counter products. Sales
growth was driven by U.S. growth in over-the-counter products including TYLENOL analgesics and digestive health
products; LISTERINE mouthwash in oral care products; OGX in skin health/beauty products; and wound care products,
primarily BAND-AID® Brand Adhesive Bandages.
Pharmaceutical
Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 4.7%*
driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for
the treatment of a number of immune-mediated inflammatory diseases, IMBRUVICA (ibrutinib), an oral, once-daily
therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, INVEGA
SUSTENNA/XEPLION/INVEGA 	TRINZA/TREVICTA 	(paliperidone 	palmitate), 	long-acting, 	injectable 	atypical
antipsychotics for the treatment of schizophrenia in adults, OPSUMIT (macitentan), an oral endothelin receptor
antagonist indicated for the treatment of pulmonary arterial hypertension to delay disease progression, UPTRAVI
(selexipag), an oral prostacyclin receptor agonist used to treat pulmonary arterial hypertension and reduce
hospitalization, and ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of
patients with prostate cancer. This growth was partially offset by the negative impact of COVID-19 as well as biosimilar
and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for the treatment of a
number of immune-mediated inflammatory diseases, and ZYTIGA (abiraterone acetate), an oral, once-daily medication
for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer.
Medical Devices
Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, declined by
3.3%*. The decline was primarily driven by the negative impact of the COVID-19 pandemic and the associated deferral
of medical procedures to our Surgery, Orthopaedics, and Vision businesses. Results reflect market recovery versus
the second quarter. The decline was partially offset by growth in the Interventional Solutions business led by
electrophysiology products.

-- 3 of 18 --

4
NOTABLE NEW ANNOUNCEMENTS IN THE QUARTER:
The information contained in this section should be read in conjunction with Johnson & Johnson’s other disclosures
filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on
Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov,
www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news
releases available online in the Investors section of the Company’s website at news releases.
Regulatory
Approvals
THERMOCOOL SMARTTOUCH – Biosense Webster Receives FDA
Approval for SF Ablation Catheter for the Treatment of Persistent Atrial
Fibrillation¹
(press release)
SIMPONI ARIA (golimumab) – Approved by the U.S. Food and Drug
Administration for Active Polyarticular Juvenile Idiopathic Arthritis and
Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age
and Older
(press release)
SPRAVATO (esketamine) – Janssen Announces U.S. FDA Approval of CIII
Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive
Disorder with Acute Suicidal Ideation or Behavior
(press release)
DARZALEX (daratumumab) – U.S. FDA Approves New DARZALEX-Based
Combination Regimen for Patients with Relapsed/Refractory Multiple
Myeloma
(press release)
STELARA (ustekinumab) – U.S. Food and Drug Administration Approves
Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
(press release)
Regulatory
Submissions
UPTRAVI (selexipag) – Janssen Submits New Drug Application (NDA) to
U.S. FDA for Injection for Intravenous Use to Treat Pulmonary Arterial
Hypertension (PAH)
(press release)
DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) – Janssen
Submits Application Seeking U.S. FDA Approval for the Treatment of Patients
with Light Chain (AL) Amyloidosis
(press release)
Other 	Johnson & Johnson Announces European Commission Approval of
Agreement to Supply 200 Million Doses of Janssen's COVID-19 Vaccine
Candidate ¹
(press release)
Johnson & Johnson Completes Acquisition of Momenta Pharmaceuticals,
Inc.¹
(press release)
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's
COVID-19 Vaccine Candidate
(press release)
CERENOVUS Launches New Suite of Technologies to Advance Stroke
Treatment
(press release)

-- 4 of 18 --

5
Johnson & Johnson Announces that Janssen’s COVID-19 Investigational
Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies
(press release)
Janssen to Discontinue Pimodivir Influenza Development Program 	(press release)
Johnson & Johnson Announces Agreement with U.S. Government for 100
Million Doses of Investigational COVID-19 Vaccine
(press release)
U.S. FDA Grants Ethicon Breakthrough Device Designation for Monarch-
enabled NeuWave Microwave Ablation Technology
(press release)
1 Subsequent to the quarter

-- 5 of 18 --

6
FULL-YEAR 2020 GUIDANCE:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the Company is
unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses,
acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items
are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in
accordance with GAAP.
The estimated impact of the COVID-19 pandemic is included in the guidance below.
October 2020 	July 2020
($ in Billions, except EPS)
Adjusted Operational Sales 1,2
Change vs. Prior Year 0.5% – 1.5% 	(0.8%) – 1.0%
Operational Sales 2
Change vs. Prior Year
$82.0 to $82.8
0.0% – 1.0%
$81.0 to $82.5
(1.3%) – 0.5%
Estimated Reported Sales 3
Change vs. Prior Year
$81.2 to $82.0
(1.0%) – 0.0%
$79.9 to $81.4
(2.6%) – (0.8%)
Adjusted Operational EPS (Diluted) 2,4
Change vs. Prior Year
$7.95 to $8.05
(8.4%) - (7.3%)
$7.85 to $8.05
(9.6%) - (7.3%)
Adjusted EPS (Diluted) 3,4
Change vs. Prior Year
$7.95 to $8.05
(8.4%) – (7.3%)
$7.75 to $7.95
(10.7%) – (8.4%)
1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2 Non-GAAP financial measure; excludes the impact of translational currency
3 Calculated using Euro Average Rate: October 2020 = $1.14 Euro Average Rate: July 2020 = $1.12 (Illustrative purposes only)
4 Non-GAAP financial measure; excludes intangible amortization expense and special items
Other modeling considerations will be provided on the webcast.
WEBCAST INFORMATION:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m.,
Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting
the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast
in the Investors section of the Company's website at events-and-presentations.
ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward
progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life.
Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and
size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind,
body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to
profoundly change the trajectory of health for humanity.

-- 6 of 18 --

7
NON-GAAP FINANCIAL MEASURES:
*Operational sales growth excluding the impact of translational currency, adjusted operational sales growth excluding
the net impact of acquisitions and divestitures and translational currency, as well as adjusted net earnings, adjusted
diluted earnings per share and adjusted operational diluted earnings per share excluding after-tax intangible
amortization expense and special items, are non-GAAP financial measures and should not be considered
replacements for, and should be read together with, the most comparable GAAP financial measures. Except for
guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP
financial measures can be found in the accompanying financial schedules of the earnings release and the Investors
section of the Company's website at quarterly-results.
Copies of the financial schedules accompanying this earnings release are available on the Company’s website at
quarterly-results. These schedules include supplementary sales data, a condensed consolidated statement of
earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information
on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected
compounds in late stage development and a copy of today’s earnings call presentation can also be found in the
Investors section of the Company's website at quarterly-results.
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of
1995 regarding, among other things: future operating and financial performance, product development, market position
and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are
based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks
or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson &
Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global
pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented
in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to
the business, or on the Company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic,
economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological
advances, new products and patents attained by competitors; challenges inherent in new product research and
development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial
success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the
Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing
difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls
or regulatory action; significant adverse litigation or government action, including related to product liability claims;
changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health
care cost containment; changes in behavior and spending patterns of purchasers of health care products and services;
financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health
care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can
be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including
in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in
the Company’s most recently filed Quarterly Report on Form 10-Q and the Company’s subsequent filings with the
Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on
request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of
this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new
information or future events or developments.
Press Contacts: 	Investor Contacts:
Cristal Downing 	Christopher DelOrefice 	Jennifer McIntyre
(732) 524-3283 	(732) 524-2955 	(732) 524-3922
(908) 616-8833 (M)
###

-- 7 of 18 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2020 	2019 	Total 	Operations 	Currency 	2020 	2019 	Total 	Operations 	Currency
Sales to customers by
segment of business
Consumer Health
U.S. 	1,556	$ 	1,394 	11.6 % 	11.6 	- 	4,853	$ 	4,369 	11.1 % 	11.1 	-
International 	1,958 	2,075 	(5.6) 	(2.7) 	(2.9) 	5,582 	5,962 	(6.4) 	(2.2) 	(4.2)
3,514 	3,469 	1.3 	3.0 	(1.7) 	10,435 	10,331 	1.0 	3.4 	(2.4)
Pharmaceutical
U.S. 	6,438 	6,340 	1.5 	1.5 	- 	18,619 	17,705 	5.2 	5.2 	-
International 	4,980 	4,537 	9.7 	8.8 	0.9 	14,685 	13,945 	5.3 	7.4 	(2.1)
11,418 	10,877 	5.0 	4.6 	0.4 	33,304 	31,650 	5.2 	6.1 	(0.9)
Medical Devices
U.S. 	3,092 	3,057 	1.2 	1.2 	- 	7,852 	9,249 	(15.1) 	(15.1) 	-
International 	3,058 	3,326 	(8.1) 	(8.5) 	0.4 	8,518 	10,082 	(15.5) 	(14.1) 	(1.4)
6,150 	6,383 	(3.6) 	(3.9) 	0.3 	16,370 	19,331 	(15.3) 	(14.6) 	(0.7)
U.S. 	11,086 	10,791 	2.7 	2.7 	- 	31,324 	31,323 	0.0 	0.0 	-
International 	9,996 	9,938 	0.6 	0.6 	0.0 	28,785 	29,989 	(4.0) 	(1.7) 	(2.3)
Worldwide 	21,082	$ 	20,729 	1.7 	1.7 	0.0 	60,109	$ 	61,312 	(2.0) 	(0.8) 	(1.2)
NINE MONTHS
Percent Change
Note: Percentages have been calculated using actual, non-rounded figures
and, therefore, may not recalculate precisely.
THIRD QUARTER

-- 8 of 18 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2020 	2019 	Total 	Operations 	Currency 	2020 	2019 	Total 	Operations 	Currency
Sales to customers by
geographic area
U.S. 	11,086	$ 	10,791 	2.7 % 	2.7 	- 	31,324	$ 	31,323 	0.0 % 	0.0 	-
Europe 	4,819 	4,461 	8.0 	4.6 	3.4 	13,709 	13,803 	(0.7) 	0.1 	(0.8)
Western Hemisphere excluding U.S. 	1,296 	1,488 	(12.9) 	(1.2) 	(11.7) 	3,931 	4,446 	(11.6) 	(0.4) 	(11.2)
Asia-Pacific, Africa 	3,881 	3,989 	(2.7) 	(3.2) 	0.5 	11,145 	11,740 	(5.1) 	(4.3) 	(0.8)
International 	9,996 	9,938 	0.6 	0.6 	0.0 	28,785 	29,989 	(4.0) 	(1.7) 	(2.3)
Worldwide 	21,082	$ 	20,729 	1.7 % 	1.7 	0.0 	60,109	$ 	61,312 	(2.0) % 	(0.8) 	(1.2)
NINE MONTHS
Percent Change
Note: Percentages have been calculated using actual, non-rounded figures
and, therefore, may not recalculate precisely.
THIRD QUARTER

-- 9 of 18 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent 	Percent 	Increase
Amount 	to Sales 	Amount 	to Sales 	(Decrease)
Sales to customers 	21,082	$ 	100.0 	20,729	$ 	100.0 	1.7
Cost of products sold 	6,972 	33.1 	6,867 	33.1 	1.5
Gross Profit 	14,110 	66.9 	13,862 	66.9 	1.8
Selling, marketing and administrative expenses 	5,431 	25.8 	5,374 	26.0 	1.1
Research and development expense 	2,840 	13.5 	2,599 	12.5 	9.3
In-process research and development 	138 	0.6 	- 	-
Interest (income) expense, net 	32 	0.1 	(41) 	(0.2)
Other (income) expense, net 	1,200 	5.7 	4,214 	20.3
Restructuring 	68 	0.3 	69 	0.4
Earnings before provision for taxes on income 	4,401 	20.9 	1,647 	7.9 	167.2
Provision for/(Benefit from) taxes on income 	847 	4.0 	(106) 	(0.6)
Net earnings 	3,554	$ 	16.9 	1,753	$ 	8.5 	102.7
Net earnings per share (Diluted) 	1.33	$ 	0.66	$ 	101.5
Average shares outstanding (Diluted) 	2,669.3 	2,669.9
Effective tax rate 	19.2 % 	(6.4) %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 	7,246	$ 	34.4 	7,116	$ 	34.3 	1.8
Net earnings 	5,868	$ 	27.8 	5,672	$ 	27.4 	3.5
Net earnings per share (Diluted) 	2.20	$ 	2.12	$ 	3.8
Effective tax rate 	19.0 % 	20.3 %
(1) See Reconciliation of Non-GAAP Financial Measures.
THIRD QUARTER
2020 	2019

-- 10 of 18 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent 	Percent 	Increase
Amount 	to Sales 	Amount 	to Sales 	(Decrease)
Sales to customers 	60,109	$ 	100.0 	61,312	$ 	100.0 	(2.0)
Cost of products sold 	20,613 	34.3 	20,422 	33.3 	0.9
Gross Profit 	39,496 	65.7 	40,890 	66.7 	(3.4)
Selling, marketing and administrative expenses 	15,627 	26.0 	16,139 	26.3 	(3.2)
Research and development expense 	8,127 	13.5 	8,123 	13.3 	0.0
In-process research and development 	144 	0.3 	890 	1.4
Interest (income) expense, net 	16 	0.0 	(43) 	(0.1)
Other (income) expense, net 	545 	0.9 	2,509 	4.1
Restructuring 	187 	0.3 	162 	0.3
Earnings before provision for taxes on income 	14,850 	24.7 	13,110 	21.4 	13.3
Provision for taxes on income 	1,874 	3.1 	2,001 	3.3 	(6.3)
Net earnings 	12,976	$ 	21.6 	11,109	$ 	18.1 	16.8
Net earnings per share (Diluted) 	4.86	$ 	4.13	$ 	17.7
Average shares outstanding (Diluted) 	2,670.8 	2,688.1
Effective tax rate 	12.6 % 	15.3 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 	19,827	$ 	33.0 	22,597	$ 	36.9 	(12.3)
Net earnings 	16,468	$ 	27.4 	18,283	$ 	29.8 	(9.9)
Net earnings per share (Diluted) 	6.17	$ 	6.80	$ 	(9.3)
Effective tax rate 	16.9 % 	19.1 %
(1) See Reconciliation of Non-GAAP Financial Measures.
NINE MONTHS
2020 	2019

-- 11 of 18 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	2020 	2019 	2020 	2019
Net Earnings, after tax- as reported 	$3,554 	$1,753 	$12,976 	$11,109
Pre-tax Adjustments
Intangible Asset Amortization expense 	1,181 	1,138 	3,426 	3,386
Litigation expense, net 	1,477 	4,000 	2,210 	4,832
IPR&D 	138 	- 	144 	890
Restructuring related 	130 	128 	363 	360
Acquisition and Integration related ¹ 	(154) 	107 	(1,087) 	229
Unrealized (gains)/losses on securities 	32 	89 	(174) 	(217)
Medical Device Regulation 2 	38 	- 	89 	-
Other 	3 	7 	6 	7
Tax Adjustments
Tax impact on special item adjustments 3 	(482) 	(1,159) 	(1,002) 	(1,922)
Tax legislation and related impacts 	(49) 	(391) 	(483) 	(391)
Adjusted Net Earnings, after tax 	$5,868 	$5,672 	$16,468 	$18,283
Average shares outstanding (Diluted) 	2,669.3 	2,669.9 	2,670.8 	2,688.1
Adjusted net earnings per share (Diluted) 	$2.20 	$2.12 	$6.17 	$6.80
Operational adjusted net earnings per share (Diluted) 	$2.17 	$6.18
Notes:
1
2
3 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the
above pre-tax special items in arriving at adjusted earnings.
Third Quarter 	Nine Months Ended
Acquisition and integration related costs for 2020 primarily includes a Contingent Consideration reversal ($165M in third
quarter and $1,148M in nine months) related to the timing of certain developmental milestones associated with the Auris
Health acquisition.
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously
registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework,
and manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May 2021.
The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of
on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its
Medical Devices operating segments' measures of profit and loss used for making operating decisions and assessing
performance.

-- 12 of 18 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	1.3% 	5.0% 	(3.6)% 	1.7%
U.S. 	11.6% 	1.5% 	1.2% 	2.7%
International 	(5.6)% 	9.7% 	(8.1)% 	0.6%
WW Currency 	(1.7) 	0.4 	0.3 	0.0
U.S. 	- 	- 	- 	-
International 	(2.9) 	0.9 	0.4 	0.0
WW Operational 	3.0% 	4.6% 	(3.9)% 	1.7%
U.S. 	11.6% 	1.5% 	1.2% 	2.7%
International 	(2.7)% 	8.8% 	(8.5)% 	0.6%
General Surgery
Advanced Sterilization Products 	0.5 	0.2
U.S. 	0.0 	0.0
International 	0.9 	0.4
Baby Care
Baby Center 	0.1 	0.0
U.S. 	0.4 	0.1
International 	0.0 	0.0
All Other Acquisitions and Divestitures 	0.0 	0.1 	0.0 	0.1
U.S. 	0.0 	0.0 	0.1 	0.0
International 	(0.1) 	0.3 	0.0 	0.1
WW Adjusted Operational 	3.1% 	4.7% 	(3.3)% 	2.0%
U.S. 	12.0% 	1.5% 	1.3% 	2.8%
International 	(2.8)% 	9.2% 	(7.6)% 	1.1%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
THIRD QUARTER 2020 ACTUAL vs. 2019 ACTUAL
Segments

-- 13 of 18 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	1.0% 	5.2% 	(15.3)% 	(2.0)%
U.S. 	11.1% 	5.2% 	(15.1)% 	0.0%
International 	(6.4)% 	5.3% 	(15.5)% 	(4.0)%
WW Currency 	(2.4) 	(0.9) 	(0.7) 	(1.2)
U.S. 	- 	- 	- 	-
International 	(4.2) 	(2.1) 	(1.4) 	(2.3)
WW Operational 	3.4% 	6.1% 	(14.6)% 	(0.8)%
U.S. 	11.1% 	5.2% 	(15.1)% 	0.0%
International 	(2.2)% 	7.4% 	(14.1)% 	(1.7)%
Skin Health / Beauty
Dr. Ci Labo - Japan 	(0.1) 	0.0
U.S. 	0.0 	0.0
International 	(0.2) 	0.0
General Surgery
Advanced Sterilization Products 	0.9 	0.3
U.S. 	0.8 	0.3
International 	0.9 	0.4
Baby Care
Baby Center 	0.2 	0.0
U.S. 	0.6 	0.1
International 	0.0 	0.0
All Other Acquisitions and Divestitures 	(0.1) 	0.2 	0.0 	0.1
U.S. 	0.0 	0.0 	0.0 	0.0
International 	(0.1) 	0.3 	0.0 	0.1
WW Adjusted Operational 	3.4% 	6.3% 	(13.7)% 	(0.4)%
U.S. 	11.7% 	5.2% 	(14.3)% 	0.4%
International 	(2.6)% 	7.7% 	(13.1)% 	(1.3)%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
NINE MONTHS 2020 ACTUAL vs. 2019 ACTUAL
Segments

-- 14 of 18 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
2020 	2019 	Reported 	Operational (1) Currency 	2020 	2019 	Reported 	Operational (1) Currency
CONSUMER HEALTH SEGMENT (2,3)
OTC
US 	601	$ 	477 	26.0% 	26.0% 	- 	1,917	$ 	1,468 	30.6% 	30.6% 	-
Intl 	541 	621 	-12.9% 	-12.9% 	0.0% 	1,722 	1,781 	-3.3% 	-0.6% 	-2.7%
WW 	1,142 	1,098 	4.0% 	4.0% 	0.0% 	3,639 	3,249 	12.0% 	13.5% 	-1.5%
SKIN HEALTH / BEAUTY
(4)
US 	572 	559 	2.4% 	2.4% 	- 	1,767 	1,810 	-2.4% 	-2.4% 	-
Intl 	577 	592 	-2.7% 	-0.5% 	-2.2% 	1,506 	1,633 	-7.8% 	-4.9% 	-2.9%
WW 	1,149 	1,151 	-0.2% 	0.9% 	-1.1% 	3,273 	3,443 	-5.0% 	-3.6% 	-1.4%
ORAL CARE
US 	164 	156 	5.5% 	5.5% 	- 	510 	462 	10.4% 	10.4% 	-
Intl 	248 	223 	10.7% 	14.4% 	-3.7% 	694 	673 	3.0% 	7.9% 	-4.9%
WW 	412 	379 	8.5% 	10.8% 	-2.3% 	1,204 	1,135 	6.0% 	8.9% 	-2.9%
BABY CARE
US 	91 	91 	-1.0% 	-1.0% 	- 	279 	277 	0.5% 	0.5% 	-
Intl 	302 	326 	-7.2% 	-0.6% 	-6.6% 	831 	977 	-14.9% 	-8.6% 	-6.3%
WW 	393 	417 	-5.9% 	-0.7% 	-5.2% 	1,110 	1,254 	-11.5% 	-6.6% 	-4.9%
WOMEN'S HEALTH
US 	3 	3 	-6.9% 	-6.9% 	- 	10 	9 	7.3% 	7.3% 	-
Intl 	227 	252 	-9.6% 	-4.0% 	-5.6% 	654 	724 	-9.6% 	-2.8% 	-6.8%
WW 	230 	255 	-9.6% 	-4.1% 	-5.5% 	664 	733 	-9.4% 	-2.7% 	-6.7%
WOUND CARE / OTHER
US 	125 	109 	15.2% 	15.2% 	- 	370 	343 	8.0% 	8.0% 	-
Intl 	64 	59 	7.4% 	10.3% 	-2.9% 	175 	173 	1.3% 	5.4% 	-4.1%
WW 	189 	168 	12.5% 	13.5% 	-1.0% 	545 	516 	5.8% 	7.2% 	-1.4%
TOTAL CONSUMER HEALTH
US 	1,556 	1,394 	11.6% 	11.6% 	- 	4,853 	4,369 	11.1% 	11.1% 	-
Intl 	1,958 	2,075 	-5.6% 	-2.7% 	-2.9% 	5,582 	5,962 	-6.4% 	-2.2% 	-4.2%
WW 	3,514	$ 	3,469 	1.3% 	3.0% 	-1.7% 	10,435	$ 	10,331 	1.0% 	3.4% 	-2.4%
See footnotes at end of schedule
% Change 	% Change

-- 15 of 18 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
PHARMACEUTICAL SEGMENT (2,5) 2020 	2019 	Reported 	Operational (1) Currency 	2020 	2019 	Reported 	Operational (1) Currency
IMMUNOLOGY
US 	2,558	$ 	2,582 	-0.9% 	-0.9% 	- 	7,330	$ 	7,124 	2.9% 	2.9% 	-
Intl 	1,230 	1,129 	9.0% 	8.4% 	0.6% 	3,619 	3,304 	9.5% 	11.9% 	-2.4%
WW 	3,789 	3,711 	2.1% 	1.9% 	0.2% 	10,950 	10,428 	5.0% 	5.7% 	-0.7%
REMICADE
US 	634 	749 	-15.4% 	-15.4% 	- 	1,852 	2,324 	-20.3% 	-20.3% 	-
US Exports (6) 78 	88 	-11.3% 	-11.3% 	- 	321 	226 	42.1% 	42.1% 	-
Intl 	209 	299 	-30.1% 	-28.0% 	-2.1% 	673 	795 	-15.3% 	-11.6% 	-3.7%
WW 	921 	1,136 	-18.9% 	-18.4% 	-0.5% 	2,846 	3,345 	-14.9% 	-14.0% 	-0.9%
SIMPONI / SIMPONI ARIA
US 	312 	313 	-0.4% 	-0.4% 	- 	840 	857 	-2.0% 	-2.0% 	-
Intl 	280 	273 	2.4% 	2.2% 	0.2% 	827 	816 	1.3% 	3.9% 	-2.6%
WW 	592 	586 	0.9% 	0.8% 	0.1% 	1,667 	1,673 	-0.4% 	0.9% 	-1.3%
STELARA
US 	1,313 	1,212 	8.4% 	8.4% 	- 	3,668 	3,152 	16.4% 	16.4% 	-
Intl 	634 	487 	30.3% 	28.1% 	2.2% 	1,795 	1,509 	19.0% 	20.6% 	-1.6%
WW 	1,947 	1,698 	14.7% 	14.0% 	0.7% 	5,463 	4,661 	17.2% 	17.7% 	-0.5%
TREMFYA
US 	222 	221 	0.4% 	0.4% 	- 	650 	565 	15.0% 	15.0% 	-
Intl 	105 	69 	54.4% 	50.4% 	4.0% 	316 	177 	78.7% 	79.1% 	-0.4%
WW 	327 	290 	13.1% 	12.2% 	0.9% 	965 	742 	30.2% 	30.3% 	-0.1%
OTHER IMMUNOLOGY
US 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
Intl 	3 	2 	35.6% 	44.6% 	-9.0% 	9 	8 	12.4% 	19.1% 	-6.7%
WW 	3 	2 	35.6% 	44.6% 	-9.0% 	9 	8 	12.4% 	19.1% 	-6.7%
INFECTIOUS DISEASES
US 	413 	418 	-1.1% 	-1.1% 	- 	1,265 	1,162 	8.9% 	8.9% 	-
Intl 	451 	421 	7.0% 	6.3% 	0.7% 	1,397 	1,385 	0.9% 	3.8% 	-2.9%
WW 	864 	839 	3.0% 	2.6% 	0.4% 	2,662 	2,547 	4.5% 	6.1% 	-1.6%
EDURANT / rilpivirine
US 	11 	12 	-12.0% 	-12.0% 	- 	33 	36 	-8.6% 	-8.6% 	-
Intl 	226 	206 	9.3% 	5.0% 	4.3% 	684 	603 	13.3% 	13.8% 	-0.5%
WW 	236 	218 	8.1% 	4.1% 	4.0% 	716 	639 	12.1% 	12.6% 	-0.5%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 	379 	373 	1.5% 	1.5% 	- 	1,154 	1,032 	11.8% 	11.8% 	-
Intl 	147 	135 	9.1% 	12.1% 	-3.0% 	461 	534 	-13.7% 	-8.8% 	-4.9%
WW 	526 	508 	3.5% 	4.3% 	-0.8% 	1,615 	1,566 	3.1% 	4.8% 	-1.7%
OTHER INFECTIOUS DISEASES
US 	24 	33 	-26.6% 	-26.6% 	- 	79 	94 	-16.6% 	-16.6% 	-
Intl 	78 	80 	-2.3% 	-0.4% 	-1.9% 	252 	248 	1.8% 	6.3% 	-4.5%
WW 	102 	113 	-9.4% 	-8.1% 	-1.3% 	331 	342 	-3.2% 	0.0% 	-3.2%
% Change 	% Change

-- 16 of 18 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
2020 	2019 	Reported 	Operational (1) Currency 	2020 	2019 	Reported 	Operational (1) Currency
NEUROSCIENCE
US 	759 	785 	-3.5% 	-3.5% 	- 	2,285 	2,172 	5.2% 	5.2% 	-
Intl 	846 	810 	4.5% 	4.1% 	0.4% 	2,565 	2,590 	-1.0% 	0.9% 	-1.9%
WW 	1,605 	1,595 	0.6% 	0.4% 	0.2% 	4,850 	4,762 	1.8% 	2.9% 	-1.1%
CONCERTA / Methylphenidate
US 	43 	84 	-49.2% 	-49.2% 	- 	150 	196 	-23.6% 	-23.6% 	-
Intl 	107 	109 	-2.0% 	-1.7% 	-0.3% 	319 	348 	-8.2% 	-6.4% 	-1.8%
WW 	149 	193 	-22.6% 	-22.5% 	-0.1% 	469 	544 	-13.8% 	-12.6% 	-1.2%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 	585 	554 	5.6% 	5.6% 	- 	1,704 	1,543 	10.5% 	10.5% 	-
Intl 	341 	297 	14.9% 	12.6% 	2.3% 	983 	916 	7.3% 	8.6% 	-1.3%
WW 	926 	851 	8.8% 	8.0% 	0.8% 	2,688 	2,459 	9.3% 	9.8% 	-0.5%
RISPERDAL CONSTA
US 	70 	79 	-11.0% 	-11.0% 	- 	220 	237 	-6.9% 	-6.9% 	-
Intl 	81 	89 	-7.8% 	-8.9% 	1.1% 	254 	292 	-12.7% 	-11.0% 	-1.7%
WW 	152 	167 	-9.3% 	-9.9% 	0.6% 	475 	528 	-10.1% 	-9.2% 	-0.9%
OTHER NEUROSCIENCE
US 	60 	68 	-11.3% 	-11.3% 	- 	210 	196 	7.1% 	7.1% 	-
Intl 	317 	316 	0.3% 	1.7% 	-1.4% 	1,008 	1,035 	-2.6% 	-0.1% 	-2.5%
WW 	377 	384 	-1.8% 	-0.6% 	-1.2% 	1,218 	1,231 	-1.1% 	1.1% 	-2.2%
ONCOLOGY
US 	1,267 	1,171 	8.2% 	8.2% 	- 	3,623 	3,146 	15.2% 	15.2% 	-
Intl 	1,862 	1,590 	17.1% 	15.5% 	1.6% 	5,310 	4,830 	9.9% 	11.8% 	-1.9%
WW 	3,129 	2,761 	13.3% 	12.4% 	0.9% 	8,933 	7,976 	12.0% 	13.1% 	-1.1%
DARZALEX
US 	585 	402 	46.0% 	46.0% 	- 	1,540 	1,123 	37.2% 	37.2% 	-
Intl 	514 	363 	41.5% 	40.5% 	1.0% 	1,397 	1,045 	33.7% 	36.7% 	-3.0%
WW 	1,099 	765 	43.8% 	43.4% 	0.4% 	2,937 	2,168 	35.5% 	37.0% 	-1.5%
ERLEADA
US 	152 	74 	* 	* 	- 	407 	194 	* 	* 	-
Intl 	55 	12 	* 	* 	* 	112 	22 	* 	* 	*
WW 	206 	86 	* 	* 	* 	519 	216 	* 	* 	*
IMBRUVICA
US 	450 	447 	0.7% 	0.7% 	- 	1,329 	1,163 	14.2% 	14.2% 	-
Intl 	581 	475 	22.5% 	21.2% 	1.3% 	1,682 	1,373 	22.5% 	25.2% 	-2.7%
WW 	1,031 	921 	11.9% 	11.2% 	0.7% 	3,011 	2,536 	18.7% 	20.2% 	-1.5%
VELCADE
US 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
Intl 	105 	149 	-30.1% 	-30.8% 	0.7% 	311 	636 	-51.2% 	-50.7% 	-0.5%
WW 	105 	149 	-30.1% 	-30.8% 	0.7% 	311 	636 	-51.2% 	-50.7% 	-0.5%
ZYTIGA / abiraterone acetate
US 	58 	233 	-75.2% 	-75.2% 	- 	284 	616 	-53.9% 	-53.9% 	-
Intl 	532 	508 	4.8% 	2.2% 	2.6% 	1,564 	1,502 	4.1% 	4.8% 	-0.7%
WW 	590 	741 	-20.4% 	-22.1% 	1.7% 	1,848 	2,118 	-12.7% 	-12.3% 	-0.4%
OTHER ONCOLOGY
US 	21 	17 	35.3% 	35.3% 	- 	63 	51 	25.8% 	25.8% 	-
Intl 	76 	83 	-8.8% 	-10.1% 	1.3% 	244 	252 	-3.1% 	-1.1% 	-2.0%
WW 	98 	100 	-1.7% 	-2.8% 	1.1% 	308 	303 	1.7% 	3.3% 	-1.6%
PULMONARY HYPERTENSION
US 	510 	427 	19.4% 	19.4% 	- 	1,541 	1,296 	18.9% 	18.9% 	-
Intl 	239 	227 	5.2% 	3.7% 	1.5% 	742 	704 	5.3% 	6.5% 	-1.2%
WW 	749 	654 	14.5% 	13.9% 	0.6% 	2,283 	2,000 	14.1% 	14.6% 	-0.5%
OPSUMIT
US 	244 	206 	18.1% 	18.1% 	- 	729 	581 	25.3% 	25.3% 	-
Intl 	148 	140 	5.5% 	3.9% 	1.6% 	458 	419 	9.3% 	10.7% 	-1.4%
WW 	392 	347 	13.0% 	12.3% 	0.7% 	1,187 	1,001 	18.6% 	19.2% 	-0.6%
UPTRAVI
US 	226 	185 	22.4% 	22.4% 	- 	692 	536 	29.1% 	29.1% 	-
Intl 	34 	25 	32.3% 	28.9% 	3.4% 	100 	75 	33.1% 	34.6% 	-1.5%
WW 	260 	210 	23.6% 	23.2% 	0.4% 	792 	611 	29.6% 	29.8% 	-0.2%
OTHER PULMONARY HYPERTENSION
US 	40 	36 	11.5% 	11.5% 	- 	121 	179 	-32.3% 	-32.3% 	-
Intl 	57 	61 	-6.7% 	-7.4% 	0.7% 	183 	210 	-12.7% 	-11.9% 	-0.8%
WW 	97 	96 	0.1% 	-0.3% 	0.4% 	304 	388 	-21.7% 	-21.3% 	-0.4%
CARDIOVASCULAR / METABOLISM / OTHER
US 	931 	955 	-2.6% 	-2.6% 	- 	2,574 	2,804 	-8.2% 	-8.2% 	-
Intl 	351 	360 	-2.7% 	-2.4% 	-0.3% 	1,052 	1,131 	-7.1% 	-4.6% 	-2.5%
WW 	1,281 	1,316 	-2.6% 	-2.5% 	-0.1% 	3,625 	3,936 	-7.9% 	-7.2% 	-0.7%
XARELTO
US 	630 	613 	2.9% 	2.9% 	- 	1,716 	1,704 	0.7% 	0.7% 	-
Intl 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
WW 	630 	613 	2.9% 	2.9% 	- 	1,716 	1,704 	0.7% 	0.7% 	-
INVOKANA / INVOKAMET
US 	156 	125 	24.7% 	24.7% 	- 	405 	411 	-1.6% 	-1.6% 	-
Intl 	68 	55 	24.7% 	25.2% 	-0.5% 	173 	147 	18.0% 	20.7% 	-2.7%
WW 	224 	179 	24.7% 	24.9% 	-0.2% 	578 	558 	3.6% 	4.3% 	-0.7%
PROCRIT / EPREX
US 	69 	126 	-45.4% 	-45.4% 	- 	215 	387 	-44.5% 	-44.5% 	-
Intl 	63 	72 	-12.2% 	-13.0% 	0.8% 	208 	220 	-5.5% 	-4.3% 	-1.2%
WW 	132 	198 	-33.3% 	-33.6% 	0.3% 	423 	607 	-30.4% 	-29.9% 	-0.5%
OTHER
US 	75 	91 	-17.9% 	-17.9% 	- 	238 	302 	-21.4% 	-21.4% 	-
Intl 	219 	234 	-6.2% 	-5.5% 	-0.7% 	670 	765 	-12.3% 	-9.5% 	-2.8%
WW 	294 	325 	-9.5% 	-9.0% 	-0.5% 	908 	1,067 	-14.9% 	-12.9% 	-2.0%
TOTAL PHARMACEUTICAL
US 	6,438 	6,340 	1.5% 	1.5% 	- 	18,619 	17,705 	5.2% 	5.2% 	-
Intl 	4,980 	4,537 	9.7% 	8.8% 	0.9% 	14,685 	13,945 	5.3% 	7.4% 	-2.1%
WW 	11,418	$ 	10,877 	5.0% 	4.6% 	0.4% 	33,304	$ 	31,650 	5.2% 	6.1% 	-0.9%
See footnotes at end of schedule
% Change 	% Change

-- 17 of 18 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
MEDICAL DEVICES SEGMENT (2,5) 2020 	2019 	Reported 	Operational (1) Currency 	2020 	2019 	Reported 	Operational (1) Currency
INTERVENTIONAL SOLUTIONS
US 	399 	357 	11.8% 	11.8% 	- 	1,019 	1,066 	-4.4% 	-4.4% 	-
Intl 	437 	382 	14.0% 	12.9% 	1.1% 	1,134 	1,156 	-2.0% 	-1.0% 	-1.0%
WW 	836 	741 	12.9% 	12.4% 	0.5% 	2,153 	2,223 	-3.1% 	-2.7% 	-0.4%
ORTHOPAEDICS
US 	1,308 	1,301 	0.6% 	0.6% 	- 	3,427 	3,950 	-13.2% 	-13.2% 	-
Intl 	774 	837 	-7.5% 	-9.0% 	1.5% 	2,145 	2,616 	-18.0% 	-16.9% 	-1.1%
WW 	2,083 	2,138 	-2.6% 	-3.1% 	0.5% 	5,572 	6,566 	-15.1% 	-14.7% 	-0.4%
HIPS
US 	221 	204 	8.7% 	8.7% 	- 	564 	633 	-10.9% 	-10.9% 	-
Intl 	124 	133 	-7.2% 	-8.4% 	1.2% 	344 	428 	-19.8% 	-18.3% 	-1.5%
WW 	345 	336 	2.4% 	1.9% 	0.5% 	908 	1,061 	-14.5% 	-13.9% 	-0.6%
KNEES
US 	205 	209 	-1.9% 	-1.9% 	- 	527 	650 	-19.0% 	-19.0% 	-
Intl 	102 	136 	-24.8% 	-26.4% 	1.6% 	298 	435 	-31.5% 	-30.7% 	-0.8%
WW 	308 	344 	-10.9% 	-11.6% 	0.7% 	825 	1,085 	-24.0% 	-23.7% 	-0.3%
TRAUMA
US 	433 	415 	4.2% 	4.2% 	- 	1,194 	1,239 	-3.6% 	-3.6% 	-
Intl 	253 	262 	-3.4% 	-4.7% 	1.3% 	698 	795 	-12.2% 	-10.9% 	-1.3%
WW 	685 	677 	1.3% 	0.7% 	0.6% 	1,892 	2,034 	-7.0% 	-6.5% 	-0.5%
SPINE, SPORTS & OTHER
(7)
US 	449 	472 	-4.9% 	-4.9% 	- 	1,142 	1,427 	-20.0% 	-20.0% 	-
Intl 	295 	306 	-3.4% 	-5.0% 	1.6% 	805 	957 	-15.8% 	-14.9% 	-0.9%
WW 	745 	778 	-4.3% 	-5.0% 	0.7% 	1,947 	2,384 	-18.3% 	-18.0% 	-0.3%
SURGERY
US 	913 	940 	-3.0% 	-3.0% 	- 	2,247 	2,867 	-21.7% 	-21.7% 	-
Intl 	1,239 	1,371 	-9.6% 	-9.5% 	-0.1% 	3,556 	4,192 	-15.2% 	-13.1% 	-2.1%
WW 	2,152 	2,311 	-6.9% 	-6.9% 	0.0% 	5,803 	7,059 	-17.8% 	-16.6% 	-1.2%
ADVANCED
US 	421 	409 	3.0% 	3.0% 	- 	1,079 	1,209 	-10.7% 	-10.7% 	-
Intl 	579 	602 	-3.9% 	-4.1% 	0.2% 	1,644 	1,811 	-9.2% 	-7.3% 	-1.9%
WW 	1,000 	1,010 	-1.1% 	-1.2% 	0.1% 	2,723 	3,019 	-9.8% 	-8.7% 	-1.1%
GENERAL
US 	492 	531 	-7.6% 	-7.6% 	- 	1,168 	1,658 	-29.6% 	-29.6% 	-
Intl 	660 	769 	-14.1% 	-13.8% 	-0.3% 	1,912 	2,381 	-19.7% 	-17.5% 	-2.2%
WW 	1,152 	1,301 	-11.4% 	-11.3% 	-0.1% 	3,080 	4,040 	-23.8% 	-22.5% 	-1.3%
VISION
US 	473 	459 	3.1% 	3.1% 	- 	1,160 	1,366 	-15.1% 	-15.1% 	-
Intl 	608 	734 	-17.2% 	-17.4% 	0.2% 	1,683 	2,117 	-20.5% 	-19.6% 	-0.9%
WW 	1,081 	1,193 	-9.4% 	-9.5% 	0.1% 	2,843 	3,483 	-18.4% 	-17.8% 	-0.6%
CONTACT LENSES / OTHER
US 	375 	339 	10.9% 	10.9% 	- 	924 	993 	-6.9% 	-6.9% 	-
Intl 	455 	555 	-18.1% 	-18.2% 	0.1% 	1,274 	1,566 	-18.7% 	-17.8% 	-0.9%
WW 	830 	893 	-7.1% 	-7.2% 	0.1% 	2,198 	2,559 	-14.1% 	-13.6% 	-0.5%
SURGICAL
US 	98 	120 	-18.9% 	-18.9% 	- 	236 	373 	-36.8% 	-36.8% 	-
Intl 	153 	180 	-14.6% 	-14.8% 	0.2% 	409 	551 	-25.7% 	-24.8% 	-0.9%
WW 	251 	299 	-16.3% 	-16.4% 	0.1% 	645 	923 	-30.2% 	-29.6% 	-0.6%
TOTAL MEDICAL DEVICES
US 	3,092 	3,057 	1.2% 	1.2% 	- 	7,852 	9,249 	-15.1% 	-15.1% 	-
Intl 	3,058 	3,326 	-8.1% 	-8.5% 	0.4% 	8,518 	10,082 	-15.5% 	-14.1% 	-1.4%
WW 	6,150	$ 	6,383 	-3.6% 	-3.9% 	0.3% 	16,370	$ 	19,331 	-15.3% 	-14.6% 	-0.7%
* Percentage greater than 100% or not meaningful 	(6) Reported as U.S. sales
(1) Operational growth excludes the effect of translational currency 	(7) Previously referred to as Spine & Other
(2) Unaudited
(3) Previously referred to as Consumer
(4) Previously referred to as Beauty
(5) Certain prior year amounts have been reclassified to conform to current year product disclosures
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.
% Change 	% Change

-- 18 of 18 --